Patrick Y Wen
Alliance for Clinical Trials in Oncology · Dana-Farber Cancer Institute · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Patrick Y Wen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:27 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07215910 · Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerAlliance for Clinical Trials in Oncology · recruiting · Astrocytoma, IDH-Mutant, Grade 3 · study chair
- Ph2NCT01380782 · BIBF 1120 for Recurrent High-Grade GliomasPatrick Y. Wen, MD · completed · Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma · principal investigator
- Ph1NCT01339039 · Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade GliomaPatrick Y. Wen, MD · terminated · High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA) · principal investigator
- Ph2NCT01249105 · MK-2206 for Recurrent Malignant GliomaDana-Farber Cancer Institute · withdrawn · Malignant Glioma · principal investigator
- Ph2NCT00859040 · Monthly SOM230C for Recurrent or Progressive MeningiomaPatrick Y. Wen, MD · completed · Meningioma · principal investigator
- Ph1/Ph2NCT00859222 · LBH589 and Bevacizumab in Patients With Recurrent High Grade GliomaPatrick Y. Wen, MD · completed · Malignant Glioma · principal investigator
- Ph1/Ph2NCT00441142 · Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain TumorsPatrick Y. Wen, MD · completed · Glioblastoma Multiforme, Gliosarcoma · principal investigator
- Ph1NCT00268385 · Vorinostat and Temozolomide in Treating Patients With Malignant GliomasNational Cancer Institute (NCI) · active not recruiting · Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma · principal investigator
- Ph2NCT00165477 · Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeDana-Farber Cancer Institute · completed · Glioblastoma, Gliosarcoma, Malignant Gliomas · principal investigator
- Ph2NCT00047294 · Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeDana-Farber Cancer Institute · completed · Brain and Central Nervous System Tumors · study chair
- Ph2NCT00047281 · Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant GliomaDana-Farber Cancer Institute · completed · Brain and Central Nervous System Tumors · study chair
- Ph1/Ph2NCT00010049 · Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or MeningiomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Brain and Central Nervous System Tumors · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Therapeutics Studies of Primary CNS MalignanciesU01CA062407 · NCI · DANA-FARBER CANCER INST · fiscal years 2000 to 2008 · $142,136 awarded in 2008Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- U01CA137443RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00268385
- U01CA062399RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00268385
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT00047294, NCT00047281
Most cited trial papers
Clinical-trial papers with this author name in glioma, ranked by citations from NIH iCite, fetched 2026-11-12 12:27 UTC. The ranking covers the 200 most relevant of 131 PubMed records, and a shared surname and initials can bring in a namesake. All 131 on PubMed
- 2,011 citationsRCR 50.0
- AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell · 20071,412 citationsRCR 32.0
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.Nature · 20191,177 citationsRCR 40.5
- 1,171 citationsRCR 43.0
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.N Engl J Med · 2023686 citationsRCR 62.4
- 513 citationsRCR 15.2
- Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.J Clin Oncol · 2010425 citationsRCR 10.4
- Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.J Clin Oncol · 2000363 citationsRCR 8.9
- Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.Lancet Oncol · 2022328 citationsRCR 22.9
- Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.Clin Cancer Res · 2006319 citationsRCR 7.0